Antengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors
CD73 is an “immune checkpoint mediator”1 that interferes with anti-tumor immune responses by generating adenosine, which leads to immunosuppression in the tumor microenvironment. This Phase I study brings together a group of highly experienced Australian investigators to collaborate with Antengene. As a Phase I study, there will be intensive safety monitoring throughout the trial. Many human tumors overexpress CD73 and this expression is frequently associated with poor prognosis. Antengene R&D Day, 2021For more information, please contact:Investor Contacts:Donald LungE-mail: [email protected]Mobile: +86 18420672158PR Contacts:Peter QianE-mail: [email protected]Mobile: +86 13062747000SOURCE Antengene Corporation Limited
Source: The Guardian June 08, 2022 17:10 UTC
